Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of QAW039 (fevipiprant) in uncontrolled asthma
NCT03052517Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in asthma (3 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 52, Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 156 and 4 more. Started Mar 2017; status: terminated.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03052517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052517.